A Combined Pharmacometrics Analysis of Biomarker Distribution Under Treatment With Standard- or Low-Dose Rivaroxaban in Real-World Chinese Patients With Nonvalvular Atrial Fibrillation

Background: The rivaroxaban dose regimen for patients with nonvalvular atrial fibrillation (NVAF) is complex in Asia. Given the high interindividual variability and the risk of bleeding caused by rivaroxaban in Asians, the influencing factors and the relationship between outlier biomarkers and bleed...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Nan, Liu, Zhiyan, Xie, Qiufen, Wang, Zhe, Sun, Zhongyi, Xiang, Qian, Cui, Yimin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971662/
https://www.ncbi.nlm.nih.gov/pubmed/35370683
http://dx.doi.org/10.3389/fphar.2022.814724

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971662/
https://www.ncbi.nlm.nih.gov/pubmed/35370683
http://dx.doi.org/10.3389/fphar.2022.814724

Ejemplares similares